Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics (TVTX) management will participate in upcoming investor conferences, beginning with the Guggenheim Global Healthcare Conference on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Guggenheim Global Healthcare Conference
Presenting on Tuesday, November 10, 2026, at 8:00 a.m. ET
Stifel 2026 Healthcare Conference
Presenting on Wednesday, November 11, 2026, at 3:20 p.m. ET
UBS Global Biopharma Conference
Presenting on Monday, November 16, 2026, at 11:20 a.m. GMT
Jefferies London Healthcare Conference
Presenting on Tuesday, November 17, 2026, at 8:00 a.m. GMT
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103317035/en/
Investors:
888-969-7879
ir@travere.com
Media:
888-969-7879
mediarelations@travere.com
Source: Travere Therapeutics, Inc.